- Home
- CVM vs NLSP Comparison
CVM vs NLSP Comparison
Compare CVM & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- NLSP
- Stock Information
- Founded
- CVM 1983
- NLSP 2015
- Country
- CVM United States
- NLSP Switzerland
- Employees
- CVM N/A
- NLSP N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- NLSP Health Care
- Exchange
- CVM Nasdaq
- NLSP Nasdaq
- Market Cap
- CVM 11.8M
- NLSP 12.4M
- IPO Year
- CVM 1987
- NLSP 2021
- Fundamental
- Price
- CVM $3.46
- NLSP $2.10
- Analyst Decision
- CVM
- NLSP
- Analyst Count
- CVM 0
- NLSP 0
- Target Price
- CVM N/A
- NLSP N/A
- AVG Volume (30 Days)
- CVM 1.6M
- NLSP 275.3K
- Earning Date
- CVM 08-14-2025
- NLSP 07-22-2025
- Dividend Yield
- CVM N/A
- NLSP N/A
- EPS Growth
- CVM N/A
- NLSP N/A
- EPS
- CVM N/A
- NLSP N/A
- Revenue
- CVM N/A
- NLSP N/A
- Revenue This Year
- CVM N/A
- NLSP N/A
- Revenue Next Year
- CVM N/A
- NLSP N/A
- P/E Ratio
- CVM N/A
- NLSP N/A
- Revenue Growth
- CVM N/A
- NLSP N/A
- 52 Week Low
- CVM $1.98
- NLSP $1.30
- 52 Week High
- CVM $66.60
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- CVM 57.66
- NLSP 46.61
- Support Level
- CVM $2.24
- NLSP $2.20
- Resistance Level
- CVM $2.71
- NLSP $3.08
- Average True Range (ATR)
- CVM 0.51
- NLSP 0.25
- MACD
- CVM 0.25
- NLSP -0.06
- Stochastic Oscillator
- CVM 25.61
- NLSP 8.40
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.